Functional role of the translocator protein 18 kDa (TSPO) in depressive patients under electroconvulsive therapy (ECT)

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00026738

Enrollment

Registered

2021-12-07

Start date

2020-10-13

Completion date

Unknown

Last updated

2025-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

F32 F31 F33

Interventions

Group 1: Electroconvulsive therapy (ECT): biological treatment procedure in which a generalised seizure is induced under anaesthesia and muscle relaxation by means of short-pulse electrical stimulatio

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: -Consenting female and male patients aged 18-60 years. -Inpatients with a depressive episode (ICD-10 F31, F32, F33; HAMD-21: =17). -Only after the study procedure has been fully and thoroughly explained and patients have given written informed consent will they be included in the study.

Exclusion criteria

Exclusion criteria: -Pregnant or breastfeeding women -Drug or alcohol dependence -Dementia -Depressive episode secondary to somatic/neurological disease or substance dependence -Severe neurological or internistic concomitant disease that may falsify the examination results (e.g. fresh myocardial infarction, Cushing's disease, underlying rheumatic diseases) -Other additional severe psychiatric comorbidities -The patient cannot understand the nature and scope of the study and is therefore not capable of giving consent. -Enrolment not voluntary -Regular systemic use of steroids or non-steroidal anti-inflammatory drugs (NSAID). -Incompatibility with MR measurement (MR questionnaire)

Design outcomes

Primary

Measure	Time frame
Diagnosis and disease course: - when: for 6 timepoints: Baseline before ECT treatment, weeks 1, 2, 3, 4, 6 during ECT treatment - how: questionnaires HAMD-21, BDI	—

Secondary

Measure	Time frame
Assessment of neurosteroids (e.g. allopregnanolone), inflammatory markers (e.g. IL-1beta and mRNA), DNA (determination of TSPO polymorphism) and TSPO protein quantification from blood samples at the following time points: Baseline before ECT treatment and weeks 1, 2, 3, 4 and 6 during ECT treatment. (Total blood volume: 300 ml). MRI Session with functional, metabolic and structural imaging at baseline, week 1, 2, 3 and 4.	—

Measure

Time frame

Assessment of neurosteroids (e.g. allopregnanolone), inflammatory markers (e.g. IL-1beta and mRNA), DNA (determination of TSPO polymorphism) and TSPO protein quantification from blood samples at the following time points: Baseline before ECT treatment and weeks 1, 2, 3, 4 and 6 during ECT treatment. (Total blood volume: 300 ml). MRI Session with functional, metabolic and structural imaging at baseline, week 1, 2, 3 and 4.

—

Countries

Germany

Contacts

Public ContactNadia Falhani

Medizinische Einrichtungen des Bezirks Oberpfalz

nadia.falhani@ukr.de0941/9415081

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026